Table 2. Clinical characteristics of atopic patients (AD) and control subjects (non AD).
| AD | Non-AD | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| AD subjects | Age (months) | SCORAD | Total IgE (kUI/l) | anti Der p1 IgE (kU/L) | Sampled inflammatory area | Control subjects | Age (months) | Total IgE (kUI/l) | anti Der p1 IgE (kU/L) |
| P01 | 25.9 | 26.7 | 76 | <0.10 | hand | P05 | 33.7 | 7 | <0.10 |
| P02 | 34.4 | 31.6 | 6392 | >100.00 | face | P08 | 16.2 | ND | ND |
| P03 | 16.9 | 21.5 | ND | ND | Back of thigh | P13 | 24.3 | 35 | <0.10 |
| P04 | 35.9 | 20.7 | 3413 | >100.00 | popliteal fossa | P14 | 36.0 | 11 | <0.10 |
| P06 | 33.4 | 25.6 | 128 | 1.41 | antecubital fossa | P17 | 21.9 | 472 | <0.10 |
| P07 | 22.8 | 25.5 | 1055 | >100.00 | face | P18 | 24.7 | 67 | <0.10 |
| P09 | 16.7 | 22.2 | 39 | 5.53 | antecubital fossa | P21 | 18.0 | 117 | <0.10 |
| P10 | 36.3 | 25.5 | 308 | >100.00 | torso | P22 | 31.2 | 5 | <0.10 |
| P11 | 22.4 | 22.1 | 1564 | 0.22 | antecubital fossa | P23 | 15.2 | 8 | <0.10 |
| P12 | 13.7 | 25 | 7 | <0.10 | thigh | P24 | 17.3 | 2 | <0.10 |
| P15 | 35.5 | 33.7 | 3490 | >100.00 | antecubital fossa | P25 | 16.4 | 5 | <0.10 |
| P16 | 16.1 | 27.2 | ND | 7.59 | thigh | P27 | 31.6 | 15 | <0.10 |
| P19 | 24.0 | 31 | 855 | 0.20 | antecubital fossa | P28 | 35.9 | <2 | <0.10 |
| P20 | 35.6 | 23.5 | 36 | <0.10 | antecubital fossa | P31 | 34.1 | 6 | <0.10 |
| P26 | 23.5 | 37.2 | 48 | 1.73 | torso | P32 | 28.4 | 7 | <0.10 |
| P29 | 19.5 | 20.2 | 8 | <0.10 | antecubital fossa | P34 | 36.5 | 52 | <0.10 |
| P30 | 30.5 | 24.5 | 67 | <0.10 | antecubital fossa | P37 | 18.6 | 9 | <0.10 |
| P35 | 12.1 | 24.5 | 1352 | 0.12 | back | ||||
| P36 | 23.2 | 27.4 | 200 | 9.59 | antecubital fossa | ||||
| P38 | 15.8 | 22 | 30 | 13.10 | antecubital fossa | ||||
| P39 | 12.4 | 31.2 | 1305 | 1.13 | torso | ||||